Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Total Liabilities (2022 - 2025)

Historic Total Liabilities for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to $2.3 million.

  • 60 Degrees Pharmaceuticals' Total Liabilities rose 6065.24% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 6065.24%. This contributed to the annual value of $1.8 million for FY2024, which is 3956.68% down from last year.
  • Latest data reveals that 60 Degrees Pharmaceuticals reported Total Liabilities of $2.3 million as of Q3 2025, which was up 6065.24% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Total Liabilities registered a high of $30.2 million during Q2 2023, and its lowest value of $1.3 million during Q1 2024.
  • Its 4-year average for Total Liabilities is $9.9 million, with a median of $2.5 million in 2023.
  • As far as peak fluctuations go, 60 Degrees Pharmaceuticals' Total Liabilities tumbled by 9547.6% in 2024, and later surged by 6065.24% in 2025.
  • 60 Degrees Pharmaceuticals' Total Liabilities (Quarter) stood at $25.4 million in 2022, then plummeted by 88.27% to $3.0 million in 2023, then tumbled by 39.57% to $1.8 million in 2024, then rose by 29.82% to $2.3 million in 2025.
  • Its Total Liabilities was $2.3 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.9 million in Q1 2025.